Clinical and sociodemographic characterization of multiple myeloma patients with symptomatic relapse and/or refractory disease under treatment in Portugal: an observational, multicenter study

被引：0
|
作者：
Bergatim, Rui [1 ,2 ,3 ,4 ]
Freitas, Jose Guilherme [5 ]
Goncalves, Cristina [6 ,7 ]
Martins, Helena [8 ]
Marques, Herlander [9 ,10 ,11 ]
Coelho, Henrique [12 ]
Seabra, Patricia [6 ]
Roque, Adriana [13 ,14 ]
Ferreira, Marcio Marcio [15 ]
Pinto, Pedro [16 ]
Francisco, Ana Rita [17 ]
Tato, Joana [17 ]
Geraldes, Catarina [18 ,19 ,20 ,21 ,22 ,23 ]
机构：
[1] Univ Porto, I3S Inst Invest Inovacao Saude, P-4200135 Porto, Portugal
[2] Univ Porto, Canc Drug Resistance Grp, IPATIMUP Inst Mol Pathol & Immunol, P-4200135 Porto, Portugal
[3] Hosp Ctr Sao Joao, Clin Hematol, P-4200319 Porto, Portugal
[4] Univ Porto, Fac Med, Clin Hematol, P-4200319 Porto, Portugal
[5] Inst Portugues Oncol Porto, Serv Oncohematol, Porto, Portugal
[6] Ctr Hosp Univ Santo Antonio, Serv Hematol, Porto, Portugal
[7] Prof Auxiliar Convidada ICBAS, Lisbon, Portugal
[8] Ctr Hosp Lisboa Norte, Hosp Santa Maria, EPE, Lisbon, Portugal
[9] Hosp Braga, Serv Oncol, Braga, Portugal
[10] Ctr Clin Acad Braga CCA, Braga, Portugal
[11] CINTESIS Ctr Invest Tecnl & Serv Saude, Porto, Portugal
[12] Ctr Hosp Vila Nova de Gaia Espinho EPE, Vila Nova De Gaia, Portugal
[13] Ctr Hosp & Univ Coimbra, Clin Hematol, Coimbra, Portugal
[14] Univ Coimbra, Inst Physiol, Fac Med, Coimbra, Portugal
[15] Braga Hosp, Clin Hematol, Braga, Portugal
[16] Ctr Hosp Vila Nova de Gaia Espinho, Clin Hematol, Vila Nova De Gaia, Portugal
[17] Takeda Farmaceut Portugal, Lisbon, Portugal
[18] Ctr Hosp & Univ Coimbra, Clin Hematol, Coimbra, Portugal
[19] Univ Coimbra, Fac Med, Lab Oncobiol & Hematol, Coimbra, Portugal
[20] Univ Coimbra, Fac Med, Clin Univ Hematol, Coimbra, Portugal
[21] Univ Coimbra, Fac Med, Coimbra Inst Clin & Biomed Res ICBR, Grp Invest Ambiente Genet & Oncobiogia CIMAGO, Coimbra, Portugal
[22] Ctr Inovacao Biomed & Biotecnol, Coimbra, Portugal
[23] Ctr Acad Clin Coimbra, Coimbra, Portugal
来源：
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA | 2023年 / 23卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P-235
引用
收藏
页码：S165 / S165
页数：1
相关论文
共 50 条
  • [31] POMALIDOMIDE SAFETY IN HABITUAL CLINICAL PRACTICE IN PATIENTS WITH MULTIPLE MYELOMA IN RELAPSE/REFRACTORY IN FUNCTION OF THE LAST PRIOR TREATMENT. SPANISH PATIENTS INCLUDED IN THE EUROPEAN SECURITY POSTAUTORIZATION STUDY
    Ramirez Payer, A.
    Duran, M. S.
    Garcia, R.
    Sampol, A.
    Gironella, M.
    Capote, F. J.
    Lopez Martinez, A.
    Cabrera Silva, C.
    Casanova, M.
    Bustamante, G.
    Garcia de Coca, A.
    Perez Persona, E.
    Rios Rull, P.
    Rosettani, B.
    Kueenburg, E.
    Navarro Vidal, M.
    Lopez Oliver, S.
    Lavilla Rubira, E.
    HAEMATOLOGICA, 2019, 104 : 200 - 201
  • [32] Novel Therapies for the Treatment of Patients with Relapsed/Refractory Multiple Myeloma: A Review of Clinical Trials
    Iftikhar, Ahmad
    Ahmad, Muhammad
    Pachika, Pranali
    Razzaq, Faryal
    Ali, Muhammad Ashar Ashar
    Farrukh, Hizra
    Latif, Azka
    Anwer, Faiz
    BLOOD, 2020, 136
  • [33] Treatment of relapsed/refractory multiple myeloma patients with lenalidomide/dexamethasone in routine clinical practice
    Schwarzer, A.
    Fruehauf, S.
    Knigsmann, M.
    Schnell, R.
    Reeb, M.
    Heits, F.
    Tirier, C.
    Prange-Krex, G.
    Knauf, W.
    Bachinger, A.
    Weiligmann, C.
    Hoppe, G.
    Glasmacher, A.
    Schmidt, B.
    ONCOLOGY RESEARCH AND TREATMENT, 2014, 37 : 291 - 291
  • [34] Teclistamab is safe and effective in relapse refractory multiple myeloma patients with end stage renal disease: a case series
    Hagen, Patrick
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2023, 23 : S183 - S183
  • [35] CLINICAL CHARACTERISTICS, TREATMENT PATTERNS AND HEALTH CARE RESOURCE UTILIZATION AMONG ITALIAN PATIENTS WITH RELAPSED REFRACTORY MULTIPLE MYELOMA: RESULTS FROM A PROSPECTIVE OBSERVATIONAL STUDY
    Palumbo, A.
    Zagorska, A.
    Popov, S.
    Zyczynski, T.
    Davis, C.
    Di Rienzo, P.
    HAEMATOLOGICA, 2016, 101 : 595 - 595
  • [36] Clinical study of fludarabine, mitoxantrone, and dexamethasone in the treatment of refractory or relapsed multiple myeloma.
    Luo, SK
    Li, J
    Hong, WD
    Zhao, Y
    Tong, XZ
    BLOOD, 2005, 106 (11) : 380B - 380B
  • [37] Real-World Clinical Outcomes in Patients with Relapse and Refractory Multiple Myeloma Received VTD-PACE Treatment in the Era of Monoclonal Antibody
    Yogo, Moe
    Kikuchi, Taku
    Tsukada, Nobuhiro
    Kunisada, Kodai
    Okda, Yuki
    Sato, Kota
    Ogura, Mizuki
    Takei, Tomomi
    Abe, Yu
    Suzuki, Kenshi
    Ishida, Tadao
    BLOOD, 2023, 142
  • [38] Characterization and Outcomes of Spanish Patients With Relapsed/Refractory Multiple Myeloma Included in the LocoMMotion Study
    Mateos, Maria-Victoria
    Weisel, Katja
    Diels, Joris
    Arribas, Alberto
    Tamayo, Maria
    Schecter, Jordan M.
    Roccia, Tito
    Haddad, Imene
    Pacaud, Lida
    Moreau, Philippe
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2024, 24 (04): : 224 - 231.e2
  • [39] Salvage Autologous Stem Cell Transplant for the Treatment of First Relapse Multiple Myeloma: Evidence of Its Clinical Role from a Multicenter Italian Study
    Mangiacavalli, Silvia
    Derudas, Daniele
    Belotti, Angelo
    Zamagni, Elena
    Paris, Laura
    Pavone, Vincenzo
    Mina, Roberto
    Di Renzo, Nicola
    Fazio, Francesca
    Tarantini, Giuseppe
    Pezzatti, Sara
    Palumbo, Gaetano
    Marcatti, Magda
    Vincelli, Jolanda Donatella
    Cafro, Anna Maria
    Falcone, Antonietta Pia
    Zambello, Renato
    Conticello, Concetta
    Mazza, Rita
    Di Raimondo, Francesco
    Pompa, Alessandra
    Martino, Enrica Antonia
    Morabito, Fortunato
    Stefanoni, Paola
    Barila, Gregorio
    Farina, Francesca
    Cartia, Claudio Salvatore
    Casson, Andrea
    Ferretti, Virginia
    Fresi, Eleonora
    Arcaini, Luca
    Petrucci, Maria Teresa
    Gentile, Massimo
    BLOOD, 2023, 142
  • [40] Clinical and pharmacokinetic phase II study of fotemustine in refractory and relapsing multiple myeloma patients
    Dumontet, C
    Jaubert, J
    Sebban, C
    Bouafia, F
    Ardiet, C
    Tranchand, B
    Berger, E
    Lucas, C
    Guyotat, D
    Coiffier, B
    ANNALS OF ONCOLOGY, 2003, 14 (04) : 615 - 622
12345